The Know ALL website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so they may not be exact or complete; Know ALL cannot guarantee the accuracy of translated content. Know ALL and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help. The interviews webpage also uses YouTube, where subtitles and translations are generated automatically by AI; please be advised to exercise caution when precise interpretation is required. For further support with YouTube, visit YouTube Help.
What treatment strategies are being used in relapsed acute lymphoblastic leukemia?
Elias Jabbour
August 6, 2021
During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, Know ALL spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US.
We asked, What treatment strategies are being used in relapsed acute lymphoblastic leukemia? In this video, Jabbour explains how we have been able to increase survival and remission rates through a targeted approach, using new drugs like bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T-cells. He highlights that the outcomes of patients with relapsed acute lymphoblastic leukemia have been improving significantly and will continue to do so.
